Bio-Technology General Corp. Announces Senior Management Promotions.

Business Editors/Health/Medical Writers

BIOWIRE2K

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--March 5, 2003

Bio-Technology General Corp. (NASDAQ:BTGC) today announced the following senior management promotions.

Robert M. Shaw has been promoted to the newly created position of Executive Vice President, Chief Administrative Officer. In addition to his continuing responsibilities as General Counsel and Secretary, Mr. Shaw has responsibility for core corporate functions, including Business Development, Strategic Planning, QA/QC and Regulatory Affairs. Mr. Shaw joined the Company in April 1998 as Vice President, General Counsel and was appointed Senior Vice President, General Counsel in June 1999 and Corporate Secretary in March 2000.

Dr. Andre Groenewegen, Managing Director of Rosemont Pharmaceuticals, Limited, BTG's wholly owned subsidiary in the UK, has been promoted to the additional post of Senior Vice President, Bio-Technology General Corp. Dr. Groenewegen joined the Company in September 2002 when BTG acquired Rosemont. From 1996 through September 2002, he held a number of positions within Akzo Nobel and its various business units, including Vice President, Rosemont Pharmaceuticals Corp., Director, Sales & Marketing, Organon Belgium and Luxembourg, and in the Strategy and Business Development Department of Organon International. Dr. Groenewegen holds a medical degree from the State University of Utrecht, the Netherlands.

About Bio-Technology General Corp.

Bio-Technology General Corp. is a biopharmaceutical company with a portfolio of specialty pharmaceutical products and expertise in developing, manufacturing, and marketing human health care products. Products marketed by BTG's sales force in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). BTG's UK subsidiary, Rosemont Pharmaceuticals, Limited, develops, manufactures, and markets oral liquid formulations of prescription products for the UK pharmaceutical market through its own sales force. BTG's Israeli subsidiary, Bio-Technology General, Ltd., manufactures Bio-Tropin(TM) (recombinant human growth hormone), BioLon(TM) (sodium hyaluronate), and Bio-Hep-B(R) (hepatitis B vaccine) and markets them in Israel, and manufactures Arthrease(TM) (sodium hyaluronate for osteoarthritis). Products marketed by BTG's licensees are Mircette(R) (oral contraceptive), and BioLon(TM) in the United States, and Bio-Tropin(TM), BioLon(TM), Bio-Hep-B(TM), Silkis(R) (vitamin D derivative), Arthrease(TM), and recombinant human insulin, in international markets. BTG's news releases and other information are available on the Company's website at www.btgc.com.

Arthrease is a trademark of DePuy Inc.; Mircette is a registered trademark of Organon, Inc.; Silkis is a registered trademark of Galderma.

Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission.